Diabetes, obesity & metabolismJan 17, 2025

Effects of survodutide on people with BMI over 27, analyzed by sex and starting BMI

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Mar 25, 2026

Abstract

After 46 weeks, females experienced greater reductions in bodyweight and waist circumference than males following treatment with survodutide.

Participants with a lower baseline body mass index (BMI) exhibited greater proportional reductions in bodyweight compared to those with a higher baseline BMI.
Conversely, reductions in waist circumference were greater in participants with a higher baseline BMI.
Rates of adverse events were similar across different subgroups categorized by sex and baseline BMI.
Nausea was the most commonly reported gastrointestinal adverse event in all subgroups.
Survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference compared to placebo.

Simplified

AIM: To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m. 2

MATERIALS AND METHODS: Totally 387 people (aged 18-75 years, BMI ≥27 kg/m, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance). Participants were categorized according to sex and baseline BMI. Data were analysed descriptively for the full analysis set (FAS), according to dose assigned at randomization (planned treatment) using on-treatment data or all data censored for COVID-19-related treatment discontinuations. (ClinicalTrials.gov number: NCT04667377). 2

RESULTS: After 46 weeks of survodutide treatment, females had greater reductions in bodyweight and waist circumference than males. Participants with a lower baseline BMI had greater proportional reductions in bodyweight than those with a higher baseline BMI; the trend was reversed for reductions in waist circumference. Rates of adverse events (AEs) were comparable between subgroups for sex and baseline BMI. Nausea was the most frequently reported gastrointestinal AE in all subgroups.

CONCLUSIONS: In people with a BMI ≥27 kg/m, survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI, and was tolerated at all doses tested. 2

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and did not receive payment related to the development of this manuscript. Carel W. le Roux has received personal fees from Boehringer Ingelheim, Eli Lilly, GI Dynamics, Gila Pharmaceuticals, Herbalife, Johnson & Johnson, Keyron, Novo Nordisk and Zealand Pharma outside the submitted work. Oren Steen has received research support from Alnylam, Anji, AstraZeneca, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly, Gilead, Janssen, Kowa, Medicago, Moderna, Novartis, Novo Nordisk, Pfizer, Sanofi, ViaCyte and Zucara Therapeutics; speaker bureau fees from Abbott, Amgen, AstraZeneca, Bausch Health, Boehringer Ingelheim, Eli Lilly, Janssen, LMC, Novo Nordisk and Sanofi; and consultancy fees from Amgen, Bayer, Eli Lilly, Novo Nordisk and Sanofi. Kathryn J. Lucas has nothing to disclose. Elena Startseva, Anna Unseld, Samina Ajaz Hussain and Anita M. Hennige are employees of Boehringer Ingelheim.

PubMed

Effects of survodutide on people with BMI over 27, analyzed by sex and starting BMI

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief